Altered neurochemical profile in the McGill-R-Thy1-APP rat model of Alzheimer's disease: A longitudinal in vivo1H MRS study

Journal of Neurochemistry

Volumn 123, Issue 4, 2012, Pages 532-541

  Nilsen, Linn H ^a   Melø, Torun M ^a   Sæther, Oddbjørn ^a   Witter, Menno P ^a   Sonnewald, Ursula ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

biomarkers; GABA; glutamate; metabolism; N acetylaspartate; transgenic rats

Indexed keywords

4 AMINOBUTYRIC ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINE; CREATININE; GLUTAMIC ACID; INOSITOL; N ACETYLASPARTIC ACID; TAURINE;

AGE; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN SIZE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; IN VIVO STUDY; LONGITUDINAL STUDY; MALE; METABOLITE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STAGING; SUBICULUM; TRANSGENIC RAT;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASPARTIC ACID; CHOLINE; CREATINE; DISEASE MODELS, ANIMAL; FEMALE; FRONTAL LOBE; GAMMA-AMINOBUTYRIC ACID; GENOTYPE; GLUTAMIC ACID; INOSITOL; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; RATS; RATS, TRANSGENIC;

ANIMALIA; RATTUS;

EID: 84867579571     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12003     Document Type: Article

References (61)

1. Bitsch A., Bruhn H., Vougioukas V., Stringaris A., Lassmann H., Frahm J., and, Bruck W., (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am. J. Neuroradiol. 20, 1619-1627.
2. Block W., Jessen F., Traber F., Flacke S., Manka C., Lamerichs R., Keller E., Heun R., and, Schild H., (2002) Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease. Arch. Neurol. 59, 828-834.
3. Chen S. Q., Wang P. J., Ten G. J., Zhan W., Li M. H., and, Zang F. C., (2009) Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement. Geriatr. Cogn. Disord. 28, 558-566.
4. Dedeoglu A., Choi J. K., Cormier K., Kowall N. W., and, Jenkins B. G., (2004) Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 1012, 60-65.
5. Eng L. F., Ghirnikar R. S., and, Lee Y. L., (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem. Res. 25, 1439-1451.
6. Fayed N., Modrego P. J., Rojas-Salinas G., and, Aguilar K., (2011) Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. Am. J. Alzheimers Dis. Other Demen. 26, 450-456.
7. Florian C. L., Williams S. R., Bhakoo K. K., and, Noble M. D., (1996) Regional and developmental variations in metabolite concentration in the rat brain and eye: a study using 1H NMR spectroscopy and high performance liquid chromatography. Neurochem. Res. 21, 1065-1074.
8. Forster D., Davies K., and, Williams S., (2012) Magnetic resonance spectroscopy in vivo of neurochemicals in a transgenic model of Alzheimer's disease: A longitudinal study of metabolites, relaxation time, and behavioral analysis in TASTPM and wild-type mice. Magn Reson Med. 2012 Jul 3. doi: 10.1002/mrm.24349. [Epub ahead of print].
9. Foy C. M., Daly E. M., Glover A., O'Gorman R., Simmons A., Murphy D. G., and, Lovestone S., (2011) Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment. Brain Topogr. 24, 316-322.
10. Gasparovic C., Arfai N., Smid N., and, Feeney D. M., (2001) Decrease and recovery of N-acetylaspartate/creatine in rat brain remote from focal injury. J. Neurotrauma 18, 241-246.
11. Griffith H. R., den Hollander J. A., Okonkwo O. C., O'Brien T., Watts R. L., and, Marson D. C., (2008) Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement 4, 421-427.
12. Gruetter R., (1993) Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn. Reson. Med. 29, 804-811.
13. Gylys K. H., Fein J. A., Yang F., Wiley D. J., Miller C. A., and, Cole G. M., (2004) Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am. J. Pathol. 165, 1809-1817.
14. Haass C., and, Selkoe D. J., (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
15. Hammer J., Alvestad S., Osen K. K., Skare O., Sonnewald U., and, Ottersen O. P., (2008) Expression of glutamine synthetase and glutamate dehydrogenase in the latent phase and chronic phase in the kainate model of temporal lobe epilepsy. Glia 56, 856-868.
16. Hensley K., Hall N., Subramaniam R., et al,. (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146-2156.
17. Huang W., Alexander G. E., Chang L., Shetty H. U., Krasuski J. S., Rapoport S. I., and, Schapiro M. B., (2001) Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 57, 626-632.
18. Jansen J. F., Backes W. H., Nicolay K., and, Kooi M. E., (2006) 1H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 240, 318-332.
19. Jessen F., Block W., Traber F., Keller E., Flacke S., Papassotiropoulos A., Lamerichs R., Heun R., and, Schild H. H., (2000) Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology 55, 684-688.
20. Jessen F., Gur O., Block W., et al,. (2009) A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology 72, 1735-1740.
21. Kantarci K., Reynolds G., Petersen R. C., et al,. (2003) Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. AJNR Am. J. Neuroradiol. 24, 843-849.
22. von Kienlin M., Kunnecke B., Metzger F., Steiner G., Richards J. G., Ozmen L., Jacobsen H., and, Loetscher H., (2005) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol. Dis. 18, 32-39.
23. Kim S. Y., Lee H., Kim H. J., et al,. (2011) In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia. NMR Biomed. 24, 1235-1242.
24. Kim S. Y., Jang E. J., Hong K. S., Lee C., Lee D. W., Choi C. B., Lee H., and, Choe B. Y., (2012) Acute restraint-mediated increases in glutamate levels in the rat brain: an in vivo (1)H-MRS study at 4.7 T. Neurochem. Res. 37, 740-748.
25. Klein J., (2000) Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J. Neural Transm. 107, 1027-1063.
26. Lanctot K. L., Herrmann N., Mazzotta P., Khan L. R., and, Ingber N., (2004) GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can. J. Psychiatry 49, 439-453.
27. Leon W. C., Canneva F., Partridge V., et al,. (2010) A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J. Alzheimers Dis. 20, 113-126.
28. Li Y., Rinne J. O., Mosconi L., et al,. (2008) Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 35, 2169-2181.
29. Mandybur T. I., and, Chuirazzi C. C., (1990) Astrocytes and the plaques of Alzheimer's disease. Neurology 40, 635-639.
30. Marjanska M., Curran G. L., Wengenack T. M., Henry P. G., Bliss R. L., Poduslo J. F., Jack C. R. Jr, Ugurbil K., and, Garwood M., (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl Acad. Sci. USA 102, 11906-11910.
31. Melo T. M., Nehlig A., and, Sonnewald U., (2005) Metabolism is normal in astrocytes in chronically epileptic rats: a (13)C NMR study of neuronal-glial interactions in a model of temporal lobe epilepsy. J. Cereb. Blood Flow Metab. 25, 1254-1264.
32. Mlynarik V., Cacquevel M., Sun-Reimer L., Janssens S., Cudalbu C., Lei H., Schneider B. L., Aebischer P., and, Gruetter R., (2012) Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease. J. Alzheimers Dis. 29, 1-13.
33. Moffett J. R., Ross B., Arun P., Madhavarao C. N., and, Namboodiri A. M., (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81, 89-131.
34. Mosconi L., (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease-FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486-510.
35. Mosconi L., Tsui W. H., De Santi S., Li J., Rusinek H., Convit A., Li Y., Boppana M., and, de Leon M. J., (2005) Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 64, 1860-1867.
36. Muramatsu M., Kakita K., Nakagawa K., and, Kuriyama K., (1978) A modulating role of taurine on release of acetylcholine and norepinephrine from neuronal tissues. Jpn. J. Pharmacol. 28, 259-268.
37. Narayanan S., De Stefano N., Francis G. S., et al,. (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J. Neurol. 248, 979-986.
38. Norenberg M. D., (1979) Distribution of glutamine synthetase in the rat central nervous system. J. Histochem. Cytochem. 27, 756-762.
39. Norenberg M. D., and, Martinez-Hernandez A., (1979) Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res. 161, 303-310.
40. Oberg J., Spenger C., Wang F. H., et al,. (2008) Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol. Aging 29, 1423-1433.
41. Olabarria M., Noristani H. N., Verkhratsky A., and, Rodriguez J. J., (2010) Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia 58, 831-838.
42. Ottersen O. P., Zhang N., and, Walberg F., (1992) Metabolic compartmentation of glutamate and glutamine: morphological evidence obtained by quantitative immunocytochemistry in rat cerebellum. Neuroscience 46, 519-534.
43. Paban V., Fauvelle F., and, Alescio-Lautier B., (2010) Age-related changes in metabolic profiles of rat hippocampus and cortices. Eur. J. Neurosci. 31, 1063-1073.
44. Pasantes-Morales H., and, Schousboe A., (1997) Role of taurine in osmoregulation in brain cells: mechanisms and functional implications. Amino Acids 12, 281-292.
45. Paula-Lima A. C., De Felice F. G., Brito-Moreira J., and, Ferreira S. T., (2005) Activation of GABA(A) receptors by taurine and muscimol blocks the neurotoxicity of beta-amyloid in rat hippocampal and cortical neurons. Neuropharmacology 49, 1140-1148.
46. Petito C. K., Chung M. C., Verkhovsky L. M., and, Cooper A. J., (1992) Brain glutamine synthetase increases following cerebral ischemia in the rat. Brain Res. 569, 275-280.
47. Pfefferbaum A., Adalsteinsson E., Spielman D., Sullivan E. V., and, Lim K. O., (1999) In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch. Gen. Psychiatry 56, 185-192.
48. Porchet R., Probst A., Bouras C., Draberova E., Draber P., and, Riederer B. M., (2003) Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer's disease. Proteomics 3, 1476-1485.
49. Le Prince G., Delaere P., Fages C., Lefrancois T., Touret M., Salanon M., and, Tardy M., (1995) Glutamine synthetase (GS) expression is reduced in senile dementia of the Alzheimer type. Neurochem. Res. 20, 859-862.
50. Provencher S. W., (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30, 672-679.
51. Rupsingh R., Borrie M., Smith M., Wells J. L., and, Bartha R., (2011) Reduced hippocampal glutamate in Alzheimer disease. Neurobiol. Aging 32, 802-810.
52. Serrano-Pozo A., Frosch M. P., Masliah E., and, Hyman B. T., (2011) Neuropathological alterations in Alzheimer disease, in The Biology of Alzheimer Disease, (, Selkoe D. J., Mandelkow E., and, Holtzman D. M., eds), pp. 43-65. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
53. Shiino A., Watanabe T., Shirakashi Y., Kotani E., Yoshimura M., Morikawa S., Inubushi T., and, Akiguchi I., (2012) The profile of hippocampal metabolites differs between Alzheimer's disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 32, 805-815.
54. De Souza S. W., and, Dobbing J., (1971) Cerebral edema in developing brain. I. Normal water and cation content in developing rat brain and postmortem changes. Exp. Neurol. 32, 431-438.
55. Thurston J. H., Sherman W. R., Hauhart R. E., and, Kloepper R. F., (1989) myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr. Res. 26, 482-485.
56. Tkac I., Rao R., Georgieff M. K., and, Gruetter R., (2003) Developmental and regional changes in the neurochemical profile of the rat brain determined by in vivo 1H NMR spectroscopy. Magn. Reson. Med. 50, 24-32.
57. Wang Z., Zhao C., Yu L., Zhou W., and, Li K., (2009) Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and Alzheimer disease. Acta Radiol. 50, 312-319.
58. Wiame E., Tyteca D., Pierrot N., et al,. (2010) Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia. Biochem. J. 425, 127-136.
59. Wu H., Jin Y., Wei J., Jin H., Sha D., and, Wu J. Y., (2005) Mode of action of taurine as a neuroprotector. Brain Res. 1038, 123-131.
60. Yang D., Xie Z., Stephenson D., et al,. (2011) Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510). Neuroimage 54, 2652-2658.
61. Zhang X., Liu H., Wu J., Liu M., and, Wang Y., (2009) Metabonomic alterations in hippocampus, temporal and prefrontal cortex with age in rats. Neurochem. Int. 54, 481-487.